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Abstract
HIV-1 is a complex retrovirus that uses host machinery to promote its replication. Understanding cellular proteins involved
in the multistep process of HIV-1 infection may result in the discovery of more adapted and effective therapeutic targets.
Kinases and phosphatases are a druggable class of proteins critically involved in regulation of signal pathways of eukaryotic
cells. Here, we focused on the discovery of kinases and phosphatases that are essential for HIV-1 replication but dispensable
for cell viability. We performed an iterative screen in Jurkat T-cells with a short-hairpin-RNA (shRNA) library highly enriched
for human kinases and phosphatases. We identified 14 new proteins essential for HIV-1 replication that do not affect cell
viability. These proteins are described to be involved in MAPK, JNK and ERK pathways, vesicular traffic and DNA repair.
Moreover, we show that the proteins under study are important in an early step of HIV-1 infection before viral integration,
whereas some of them affect viral transcription/translation. This study brings new insights for the complex interplay of HIV-
1/host cell and opens new possibilities for antiviral strategies.
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Introduction
Despite all the efforts in the last three decades for the
development of new drugs for acquired immune deficiency
syndrome (AIDS) treatment, human immunodeficiency virus type
1 (HIV-1)/AIDS continue to be one of the major human health
setbacks of our days [1]. HIV therapies (HAART) developed so far
(reviewed in [2]) although powerful, effective against HIV and
capable of prolonging life and health of the infected individuals,
are still not able to cure AIDS [3]. The ability of HIV to establish
latent reservoirs early on the course of infection and its capacity to
mutate at a high rate, leading to the emergency of resistant viruses,
are the major concerns for the current therapies [4]. Therefore, it
is crucial to identify novel drug targets and new therapeutic
strategies to combat AIDS. A better understanding of the virus and
host-cell interplay could hopefully provide valuable insights into
the molecular interactions involved in various steps of retroviral
replication. The knowledge of these novel critical players can lead
to the development of more adapted and effective therapeutic
approaches for eradication of HIV-1 infection [5].
During the past years, several studies have been focused in the
identification of host factors that assist HIV-1 during the different
steps of its replication cycle [5,6]. Nevertheless, due to the
complexity of the interaction between the virus and the host cell,
numerous proteins and mechanisms are yet to be discovered.
Recently, different studies using genome-wide RNA interference
(RNAi) screens were performed to discover new cellular proteins
important for HIV-1 replication [7–10]. Three of these screens
used siRNA libraries and were transiently expressed in HeLa or
HEK293T cells [7–9]. Recently, Kuan-Teh Jeang and co-workers
performed a loss of function screen with short-hairpin-RNA
(shRNAs) cloned in lentiviral vectors to allow the constitutive
expression of the shRNAs in Jurkat T-cells [10]. All these screens
are based in RNAi libraries that cover all human genes.
Nonetheless, despite using similar strategies, the degree of
functional overlap between the identified proteins in the different
screens was very low. Importantly, these studies brought
noteworthy knowledge on HIV-1/host interaction by identifying
many cellular proteins that had not yet been related to HIV-1
infection. Moreover, the diversity of identified proteins suggests a
vast complexity of host-virus interplay.
Differently than previous studies, in this work we used a smaller
library enriched for human kinases and phosphatases, narrowing
down the heterogeneity and possible off-target genes that could
result from a genome-wide RNAi screen. Similarly to the work of
Kuan-Teh Jeang and co-workers, we used Jurkat cells to access
specific T-cell genes important for HIV-1 replication but with the
additional goal of identifying cellular drug targets for an antiviral
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of HIV-1 resistant cells was dependent on viral expression (direct
readout) instead of cell death due to viral infection (indirect
readout). These differences are expected to complement and
improve the goal of discovering novel HIV-1 knockdown targets.
Amongst all proteins considered, kinases and phosphatases are
probably the most important regulators of biological and signal
pathways. These proteins are key complementary players in
protein phosphorylation, a well-characterized biochemical process
for reversible regulation of protein activity [11]. Moreover, since
kinases and phosphatases are enzymes whose catalytic activity can
be effectively and specifically turned off by active site-directed
inhibitors, they constitute nowadays the largest subset of the
druggable genome, the so-called ‘‘kinome’’ and ‘‘phosphatome’’.
Thus, we can envision that kinase/phosphatase modulation is a
promising approach for the development of novel therapeutic
strategies to overcome antiviral drug resistance [12,13]. In this
context, the study of kinase and phosphatases genes and their
function during HIV-1 replication may not only contribute to a
better knowledge of HIV-cell interaction but also may lead to the
discovery of new cellular targets for HIV-1 therapy.
With this iterative shRNA screen in Jurkat cells we identified 14
different cellular proteins, involved in several cellular pathways
that are essential for HIV-1 replication. Furthermore, our results
indicate that the majority of these proteins are not involved in viral
integration, being important during entry into the cell and/or
uncoating and also affecting viral transcription/translation.
Our results bring not only new insights to the complexity of the
HIV-1/host interaction but also open possibilities of exploring
novel therapeutic strategies for the treatment of AIDS by targeting
kinases and phosphatases.
Materials and Methods
Cell Lines and Culture Conditions
Jurkat E6-1 T-cells obtained through the NIH AIDS Research
and Reference Reagent Program (MD, USA, contributor Dr.
Arthur Weiss) were cultured in RPMI-1640, supplemented with
10% FBS (RPMI-10). HEK293T (ATCC, VA, USA) and HeLa-P4
cells (HeLa-CD4-LTR-b-gal, AIDS Reagent, MD, USA, contrib-
utor Dr. Richard Axel) were cultured inDMEMsupplemented with
10% FBS (DMEM-10). Jurkat cells expressing shRNA (shRNA
clones) were cultured in RPMI-10 supplemented with 2 mg/ml of
puromycin (Sigma, MO, USA). All cell cultures were maintained at
37uCi n5 %C O 2. All cell culture media and reagents, otherwise
indicated, were from Lonza (Basel, Switzerland).
Viral Production
HEK293T cells were transfected, by calcium phosphate
method, with pNL4-3-r-HSAS (AIDS reagent, contributors Drs.
Beth Jamieson and Jerome Zack) or pHIV-1NL4-3 plasmids (AIDS
reagent, contributor Dr. Malcolm Martin) to produce HIV-HSA
or HIV-1NL4-3 virions, respectively. After 48 h, virions were
collected from supernatant cultures, measured by p24
CA ELISA
(AIDS & Cancer Research Program, NCI Frederick, MD, USA)
and used to infect Jurkat cells.
Infection Assays
Jurkat cells, shRNA library and individual cell clones were
infected with HIV-HSA or HIV-1NL4-3 at the indicated Multi-
plicity of Infection (MOI). For this purpose, cells were ressus-
pended in a viral preparation and subject to spinoculation [14].
After 6 h, cells were washed in PBS (16) and medium was
replaced. During the 7 day-infection assay, medium was replaced
at day 4. HIV-1 replication was monitored in all experiments by
p24
CA ELISA (AIDS & Cancer Research Program).
Lentiviral shRNA Library Screen
Lentiviral shRNA library composed by 3–5 shRNA for eachgene
was enriched for human kinases and phosphatases by rearraying
LKO.1 shRNA constructs obtained from the RNAi Consortium
(TRC) (Broad Institute, MA, USA). High-titer lentiviral production
was obtained after transfection of HEK293T cells with the shRNA-
encoded library. The plasmids included in the lentiviral packaging
mix encode the key structural viral packaging genes and a
heterologous viral envelope gene in a three-plasmid lentivirus
packaging system [15]. We collected the cell supernatant containing
a highly infectious pool of VSV-G pseudotyped shRNA-encoding
lentiviral particles and used it for transduction of Jurkat cells.
Jurkat cells were transduced with the lentiviral shRNA library at
MOI of 1 and enhanced by spinoculation. Two independent
transductions were performed with the same pool, leading to two
populations of transduced Jurkat cells. Medium was replaced 24 h
later and after 48 h, cells were challenged with HIV-HSA at a
MOI of 1, washed 6 h later and cultured in RPMI-10 for 7 days as
aforementioned. Medium was replaced every 2 days.
Transduced Jurkat cells challenged with HIV-HSA were
negatively selected using a biotinylated anti-HSA antibody (BD
Pharmingen, CA, USA) and CELLection Biotin magnetic beads
(Invitrogen Dynal, Oslo, Norway), according to the manufactur-
ers’ protocol. This iterative procedure was repeated for 3 more
rounds. Cells were recovered, cultured in RPMI-10 supplemented
with 2 mg/ml of puromycin and grown for 7 days. Procedures of
viral infection, negative selection and cell culture with puromycin
were performed 3 times. The negatively-selected puromycin
resistant-cells were cloned with a ClonaCell
TM-TCS semi-solid
medium (StemCell Technologies, Vancouver, Canada) and grown
in 96-well plates with RPMI-10 supplemented with 2 mg/ml of
puromycin. The resistant cell clones were expanded and cells were
allowed to growth for 2 months.
Immunoblotting
Intracellular Gag and Vif protein expression was evaluated by
western blot. Briefly, cells were washed in ice-cold PBS and lysed
in RIPA lysis buffer for 30 min at 4uC. Protein concentration was
quantified by Bradford colorimetric assay (BioRad, CA, USA).
Equal amounts of protein were analyzed by 12% SDS-PAGE,
transferred onto nitrocellulose membranes (GE Healthcare,
Buckinghamshire, UK), blotted with anti-p24 primary antibody
(AIDS Research and Reference Reagent Program, Division of
AIDS, NIAID, NIH, #530, from Dr. Susan Zolla-Pazner), anti-vif
primary antibody (AIDS Research and Reference Reagent
Program, Division of AIDS, NIAID, NIH, #2221, from Dr.
Dana Gabuzda) and anti-GAPDH primary antibody (6C5; Santa
Cruz Biotechnology, CA, USA), followed by incubation with
HRP-conjugated secondary antibodies (BioRad) and developed
using the ECL (GE Healthcare) or Femto (Pierce, IL, USA).
EGFP-Encoding Lentiviral Particles Production and shRNA
Clones Transduction
To produce eGFP-encoding lentiviruses particles, HEK293T
cells were co-transfected with pGagPol [15], pRev [15], pFugW
[16] and pHEF-VSVG (AIDS Research and Reference Reagent
Program, Division of AIDS, NIAID, NIH, from Dr. Lung-Ji
Chang) or pSVIIIexe7pA-HxB2 [17] in the proportion of
2:1:1:0.2. After 48 h, lentiviral particles were collected and
quantified by p24
CA ELISA. shRNA clones were transduced with
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enhanced by spinoculation. After 6 h, cells were washed and
medium was replaced. After 48 h post-transduction cells were
collected for flow cytometry analysis.
Flow Cytometry Analysis
Cells transduced with HIV-HSA were harvested at 2, 4 and 7
days and cells transduced with FUGW-VSV or FUGW-GP120
were harvested after 48 h. Afterwards, washing with 1% BSA-
PBS, HIV-HSA-transduced cells were stained for HSA surface
expression (BD Pharmingen) for 30 min at 4uC. Then, cells were
washed and fixed with 0.1% formaldehyde in PBS. Cells
transduced with FUGW-VSV or with FUGW-GP120 were
washed and fixed with 0.1% formaldehyde in PBS. Labeled
untransduced cells were used as negative controls. BD FACS
Calibur (BD Bioscience, CA, USA) was used to acquire at least
10,000-gated events from each sample. Data was analyzed using
FlowJo software (Tree Star, OR, USA).
Transient Transfection Assays
HeLa-P4 cells were co-transfected with 300 ng of pLKO.1
shRNA for each target gene and 100 ng of pHIV-1NL4-3.
Transfections were performed with FuGENEH HD (Roche, IN,
USA) according to manufacturers’ protocol. After 48 h, viral
particles were collected and quantified by p24
CA ELISA. Cells
were collected to evaluate b-galactosidase expression by a colori-
metric assay, based on the cleavage of chlorophenolred-b-D-
galactopyranoside (CPRG; Roche) as described in [18].
Assessment of Cell Viability
After 7 days of infection, shRNA clones viability was
determined using the Cell Proliferation Reagent WST-1 (Roche)
according to manufacturer’s instructions.
Statistical Analysis
Statistical significance was determined using the Paired t-test.
Differences were considered statistically significant when p#0.05.
Analyses were performed using the Graphpad Prism 4.0 software
(GraphPad Software, CA, USA).
Results
shRNA Screening to Isolate HIV-1 Resistant Jurkat T-Cells
To identify host factors essential for HIV-1 replication we
developed a shRNA screen in Jurkat T-cells using a subset of the
RNAi consortium (TRC) lentiviral library highly enriched for
human kinases and phosphatases This library includes 2855 clones
corresponding to 622 human kinase genes and 735 clones
corresponding to 180 human phosphatase genes, together with
1693 clones corresponding to other human genes. The list of total
genes included in the enriched library will be disclosed upon
request. As described in Figure 1A, shRNA encoding lentiviral
particles were produced and used as a pool to transduce Jurkat
cells at an MOI of 1 (1610
6 TU/ml quantified by p24
CA ELISA).
Experimental conditions were optimized to achieve a highly
efficient VSV-G dependent lentiviral transduction of ,75% (data
not shown). Lentiviral library transduction was performed twice in
5610
6 cells to increase the odds of having all shRNAs transduced
in our Jurkat population. Due to high transduction efficiency and
the reduced number of individual clones in this library compared
to genome-wide representation, we found that the probability of
all shRNA clones to be transduced is P(A’) =0,998. Subsequently,
transduced cells were challenged with a replication competent
HIV-1 encoding murine heat stable antigen HSA used as a cell
surface marker to discriminate between infected and non-infected
cells. After 7 days of HIV-1 infection, we selected shRNA-
transduced cells HSA-surface-negative and potentially resistant to
HIV-1 replication. This procedure was performed in 3 consecutive
Figure 1. shRNA screen in Jurkat cells. A. Schematic representation of the shRNA screen. A pool of shRNA-encoding-lentiviral particles was used
to transduce Jurkat cells and after 48 h they were challenged with HIV-HSA. After 7 days of infection, the shRNA transduced cells were negatively
selected with magnetic beads conjugated with biotinylated anti-HSA. After 3 rounds of infection/selection, the HIV-1 resistant clones were recovered
and isolated. Seven-hundred shRNA Jurkat clones were obtained, expanded and allowed to growth for 2 months to identify cellular proteins essential
for HIV-1 replication in Jurkat cells but not essential for the cell viability. We obtained 180 viable shRNA clones. B. Resistance of shRNA clones to HIV-1
replication, measured by p24
CA expression in the cell culture supernatant after 7 days of infection with HIV-1NL4-3 (MOI of 1). Percentage values are
relative to Jurkat cells infected with HIV-1NL4-3. Values indicated in graph represent the number of clones isolated in each subgroup.
doi:10.1371/journal.pone.0009276.g001
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removal of HSA-expressing cells from the system. The remaining
HSA-negative cells were cultured in the presence of puromycin to
select expressing shRNA Jurkat cells. Following negative and
puromycin selections, cells were individually cloned and expanded
to evaluate resistance to HIV-1 infection.
We obtained 700 individual shRNA-transduced Jurkat cell
clones resistant to HIV-1 replication. To identify kinases and
phosphatases essential for HIV-1 replication but innocuous for
T-cell viability, individual shRNA clones were expanded and
cultured for 2 months in medium supplemented with puromy-
cin. At this period, the numbero fJ u r k a ts h R N Ac l o n e st h a t
survived was reduced to 184, which may be due to cytotoxic
effects resulting from gene knockdown in cells cultured for 60
days.
To further confirm that viable shRNA clones were resistant to
HIV-1 replication, an infection assay was performed for each
individual clone. All 184 shRNA clones were infected with HIV-
1NL4-3 with a MOI of 1. After 7 days of infection, viral replication
was measured by p24
CA ELISA in supernatant of infected cultures
and resistance to HIV-1 replication was determined. As shown in
Figure 1B, the majority of shRNA clones were highly resistant to
HIV-1 replication. Indeed, when compared to wild-type Jurkat
cells, 136 out of 184 shRNA clones exhibited more than 80%
reduction in HIV-1 replication, indicating that our original
shRNA screen was able to efficiently isolate T-cells clones resistant
to HIV-1 replication.
Identification of the shRNAs Targets
To identify HIV-1 dependent host-factors targeted by the
shRNA that were responsible for viral resistance, we selected 30
shRNA Jurkat cell clones with highest resistance to HIV-1
replication and sought to identify their shRNA sequences after
genomic DNA extraction and PCR amplification. The shRNA
clones analyzed lead to the identification of 14 different gene
targets, as described in Table 1. From the 30 sequences we have
identified cellular host-factors with only one shRNA gene-
s p e c i f i cs e q u e n c ea n dg e n e st h a tw e r et a r g e t e db ym o r et h a n
one shRNA.
As shown in Table 1, amongst the 14 host-proteins identified as
essential for HIV-1 replication we found 2 phosphatases, 5 kinases,
1 hypothetical kinase-binding-protein, 2 phosphatase-binding-
proteins and 4 other proteins with various functions. By
performing biochemical functional analysis (IPA–Ingenuity Sys-
tems) the identified proteins were clustered in two major groups:
Amino Acid Metabolism, Post-Translational Modification, Small
Molecule Biochemistry and Cell Cycle, Cell Signaling, Cellular
Growth and Proliferation [(Supporting Information S1, Figure
S1)]. The specific molecular and/or cellular functions are
represented in Figure S2A.
The identification in this screen of proteins other than kinases or
phosphatases is due to the fact that this was an enriched shRNA
library that contained other target genes besides kinases and
phosphatases. The significant number of non-kinase and non-
phosphatase genes in our output compared with its percentage in
the initial library could be justified by the strategy of long-term
screening. After two months of selection with puromycin and
infection with HIV-1, a large number of shRNA clones were not
detected. These clones may constitute a mixture of shRNA that
induced different levels of cytotoxicity in the cell. During more
than 60 days in culture, viable shRNA clones may outgrowth other
Jurkat-T-cell clones that showed decreased cytotoxicity over time.
Therefore, since kinases and phosphatases are involved in
biochemical and cell-cycle pathways essential for proliferation
and cell survival, the long-term selection method could have
eliminated the less viable clones from the final output. In this
study, we have evaluated all resultant genes including non-kinases
and non-phosphatases, except for PTPRE that was not studied due
to technical reasons.
Table 1. Proteins identified in the shRNA screen important for HIV-1 replication.
Gene Symbol Name Functional Category
# shRNA
clones
PTPN9/PTP-MEG2 Protein tyrosine phosphatase, non-receptor type 9 Member of the protein tyrosine phosphatase (PTP) family 10
PTPRE PTPRE protein tyrosine phosphatase, receptor type, E Member of the protein tyrosine phosphatase (PTP) family 1
PRKD1/PKD/PKC-MU Protein kinase D1 Member of the protein kinase C (PKC) family
Cytosolic serine/threonine kinase
2
MAP3K2/MEKK2 Mitogen-activated protein kinase kinase kinase 2 Serine/threonine protein kinase
Member of MEK kinase family
1
MAPK9/JNK2 Mitogen-activated protein kinase 9 Member of the MAP kinase family 1
SGK/SGK1 Serum/glucocorticoid regulated kinase Serine/threonine protein kinase 1
STK24/MST3 Serine/threonine kinase 24 (STE20 homolog, yeast) Upstream of the mitogen-activated protein kinase (MAPK) cascade 1
CIB2 Calcium and integrin binding family member 2 Ca
2+-binding regulatory protein that potentially interacts with DNA-
dependent protein kinase catalytic subunit (DNA-PKcs)
1
PPFIA2 Protein tyrosine phosphatase, receptor type, f
polypeptide interacting protein (liprin), alpha 2
Member of the LAR protein-tyrosine phosphatase-interacting protein
(liprin) family
PPFIBP1 PTPRF interacting protein, binding protein 1
(liprin beta 1)
Member of the LAR protein-tyrosine phosphatase-interacting protein
(liprin) family
1
RAD23B RAD23 homolog B (S. cerevisiae) Protein involved in the nucleotide excision repair (NER) 1
EZH2 Enhancer of zeste homolog 2 Member of the Polycomb-group 1
WT1 Wilms tumor 1 Transcription factor 3
ELA1/CELA1 Elastase 1, pancreatic Serine protease 4
doi:10.1371/journal.pone.0009276.t001
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Replication
Next, we wanted to exclude the possibility that integration of
shRNA lentiviral vector showed off-target effects. Thus, we
recloned 3-to-5 shRNA for each host-protein identified in the
previous assay, creating Jurkat cell lines stably expressing the
corresponding shRNA (each shRNA sequence is reported in Table
S1). The resistance of these shRNA clones to HIV-1 replication
was evaluated by replication assays (Figure S3) and the two most
efficient shRNA clones were selected. To confirm effectiveness of
the shRNA clones selected we performed a quantitative real-time
PCR (qPCR), with specific primers (Table S2), assessing mRNA
downregulation for each target gene (Figure S4). The real-time
assays were performed for all genes in study. In the majority of the
shRNA clones a denoting decrease is observed in gene-specific
mRNA levels indicating a down-modulation of the genes by the
shRNAs. However, for some shRNA clones the mRNA level
reduction was not so evident. For ELA1 gene both shRNA clones
show lower diminution in mRNA levels (figure S4E), but the
replication assays indicate a high reduction in HIV-1 replication.
These results may indicate that a slight alteration in ELA1 mRNA
levels reflects a considerable alteration in phenotype, as observed
in Figure S3E. For PPFIA2-2 and SGK-2 shRNAs, the results
showed a minor reduction in mRNA levels, although for PPFIA2-
1 and SGK-1 shRNA the knockdown is stronger (Figure S4I and
S4M).
The following studies assessing the inhibitory effect on HIV-1
replication were performed with the chosen shRNA clones.
Subsequent to clone expansion, shRNA clones were infected with
HIV-1NL4-3 at a MOI of 1 to determine the extent of viral
replication in these cells. After 7 days of infection we determined
viral replication by quantifying the amount of virion capsid protein
p24
CA in cell culture supernatant by ELISA. To assure that the
RNAi pathway was activated by the stable expression of shRNAs
and did not interfere with HIV-1 replication leading to off-target
effects, we used scrambled shRNA (shSCRAM) as control. This is
a non-specific shRNA that activates the RNAi pathway, without
targeting any human genes.
As showed in Figure 2A, HIV-1 replication was strongly
inhibited in all shRNA clones tested (over 80% of inhibition),
supporting the relevance of these host-proteins during HIV-1
replication. Importantly, inhibition of HIV-1 replication was not
due to an outcome of decrease cell viability as all shRNA clones
exhibited viability values similar to the control (Figure 2B).
To test if inhibition of HIV-1 replication was a result of a lower
viral expression or instead a reduction in viral release, we analyzed
the intracellular gag gene expression of shRNA T-cell clones by
western-blot. As shown in Figure 2C, after 7 days of infection with
HIV-1NL4-3, neither P55
Gag nor p24
CA were detected in any of the
shRNA Jurkat clones except for shSCRAM (control). These results
corroborate the p24
CA ELISA data and strengthen the important
role of targeted host-proteins in a step(s) prior to virus expression.
Efficient Knockdown Is of HIV-1 Replication Is Maintained
Overtime
To evaluate whether inhibition of HIV-1 replication in the
shRNA clones occurred early in viral replication or rather if it
would reflect a cumulative effect, we followed HIV-1 infection
over time and assessed viral spread in culture. We infected shRNA
T-cell clones with HIV-1NL4-3 and monitored viral production
overtime by measuring the p24
CA in cell culture supernatant at
day two, four and seven (Figure 3A). As represented in the three
panels of Figure 3A, we can observe a pattern of viral replication
throughout time for all different shRNA clones. Compared to
HIV-1 replication in shSCRAM cells normalized to 100% at all
time points, we observed a continuous reduction in the amount of
virus in supernatant of shRNA infected clones. p24
CA levels were
lower at day 2 (25% to 75% depending the shRNA clone) and
were constantly reduced until day 7 where nearly no p24
CA was
detected.
To determine the effect of shRNAs in the expression of a de novo
viral protein we evaluated by western-blot the expression of Vif
after 48h of HIV-1NL4-3 infection. As shown in Figure 3B, the
expression levels of Vif were barely undetectable compared to
control (shSCRAM). The greater reduction of Vif expression
(Figure 3B) compared with p24
CA levels in Figure 3A can be
explained by the detection of residual input p24
CA from virus still
present at 48 h and not resulting from a de novo replication.
Therefore, when considered together, these results indicate that
inhibition of HIV-1 replication by gene-specific shRNAs is very
effective and initiates early in HIV-1 replication. Nevertheless, for
EZH2-1 shRNA and in minor importance for EZH2-2 and
PPF1A2-2 shRNAs, expression of Vif was higher than for other
knockdowns. Taking in consideration the reduction in viral
replication observed with these gene-specific shRNA, this fact
may reflect a mechanism of HIV-1 inhibition that is subsequent to
viral expression.
To get better understanding on the blocking effect of host-
protein expression by shRNA in HIV-1 infection and dissemina-
tion in culture, we challenged the different shRNA clones with the
HIV-HSA reporter virus. This system allows HIV-1 infection to be
followed at single-cell level by enumerating HSA
+ cells by flow
cytometry after surface staining. Seven-day time course assay
demonstrated that while the percentage of shSCRAM infected
cells steadily increased from less than 10% at day 2 to
approximately 60% at day 7, the percentage of HSA
+ of all
shRNA clones remained relatively unchanged through time
(Figure 3C). In this experiment we also monitored HIV-1-HSA
replication by p24
CA ELISA and observed a similar pattern in all
shRNA clones compared to replication of the parental HIV-1
(Figure S5) indicating that both HIV-1NL4-3 and HIV-HSA
replication in the shRNA clones were performed in an akin way.
To evaluate if the lower percentage of infected cells over time
could result from the loss of CD4 expression at the cell surface, we
monitored the CD4 positive cells during 7 days of infection with
HIV-1NL4-3 (Figure S6). We observed a lack of significant decrease
of CD4 surface expression in shRNA clones compared with wild-
type Jurkat cells or shSCRAM clone.
Despite the observation that shRNAs do not completely
knockdown host-proteins gene expression (Figure S4), viral
replication was strongly reduced as demonstrated in Figure 3.
These results support the hypothesis that an effect of host-proteins
on viral replication is highly sensitive to small variations in protein
expression which is reflected in an immediate effect of shRNA.
Knockdown of Host-Proteins Do Not Affect Integration
but Rather Affect an Early Step in HIV-1 Replication
The observation that gag products were not detected intracel-
lularly, lead to the hypothesis that the identified host-proteins
would be important in an early stage of HIV-1 life cycle, before
Gag expression (Figure 2C). To further investigate whether HIV-1
replication cycle was affected before or after viral integration
knockdown-Jurkat cells were transduced with an HIV-1-based
lentiviral vector, carrying the EGFP transgene, and pseudotyped
with a VSV-G envelope. Expression of the fluorescent protein was
under the control of human ubiquitin-C promoter to avoid a
bias effect that host-proteins might be involved in LTR-driven
New HIV-1 Host-Factors
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by flow cytometry showed similar fluorescence results compared to
the control shSCRAM indicating that in all Jurkat-knockdown-
cells HIV-1 proviral vector was efficiently integrated (Figure 4,
black bars). To assess whether by using VSV-G-pseudotyped HIV-
1 vectors we were overcoming an entry defect in Jurkat
knockdown clones, similar experiments were performed with a
gp120-pseudotyped lentiviral vector. Results from transduction
Figure 2. shRNA clones are resistant to HIV-1 replication. A. Two different shRNA clones for each target gene were infected with HIV-1NL4-3
(MOI of 1) and after 7 days of infection, HIV-1 replication was measured by p24
CA levels in the cell culture supernatant. Values are relative to Jurkat
cells infected with HIV-1NL4-3 and represent the mean 6 SEM (n=6). *** corresponds to P,0,0001. B. Viability of shRNA clones after 7 days of
infection with HIV-1NL4-3. Values are relative to Jurkat cells infected with HIV-1NL4-3 and correspond to mean 6 SEM (n=4). C. Immunoblotting of
intracellular Gag protein in different shRNA clones after 7 days of HIV-1NL4-3 infection (MOI of 1). This figure is representative of three independent
experiments.
doi:10.1371/journal.pone.0009276.g002
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levels of EGFP compared to Jurkat shSCRAM (Figure 4, white
bars). Taken together, these results indicate that these newly
identified proteins do not affect viral integration but have a role
during HIV-1 entry.
HIV-1 LTR-driven transcription is affected by host-proteins.
Since these newly identified host-proteins are cellular transcription
factors we sought to assess whether its knockdown could affect Tat
transactivation of HIV-1 expression. The effect of knockdown
host-proteins was monitored in HeLa-P4 cells containing the b-
galactosidase gene under the control of the HIV-LTR. HeLa-P4
cells were transiently cotransfected with pHIV-1NL4-3 and an
individual gene-specific shRNA. The efficiency of LTR-driven
expression was determined by b-Galactosidase activity 48 h post-
transfection. By examining b-Galactosidase activity (Figure 5,
black bars), the relative expression of shRNA against PRKD1,
MAP3K2, MAPK9, RAD23B, EZH2, PPFIA2, PPFIBP1 and
WT1 exhibited a decrease on LTR-directed transcription
compared with control shSCRAM. However, no noteworthy
effect could be observed for shRNA against PTPN9, CIB2 and
Figure 3. Neutralization of HIV-1 replication by shRNAs is cumulative over time. A. Kinetics of HIV-1NL4-3 replication in shRNA Jurkat clones
during 7 days of infection. shRNA clones were infected with HIV-1NL4-3 (MOI of 1) and p24
CA antigen was measured at day 2, 4 and 7. Values are
relative to control shSCRAM cells infected with HIV-1 (&) and represent mean 6 SEM (n=3). B. Immunoblotting of Vif protein in the different shRNA
clones after 48 h of HIV-1NL4-3 infection (MOI of 1). This figure is representative of three independent experiments. C. Flow cytometry analysis of HSA
surface expression in shRNA clones infected with HIV-HSA (MOI of 1) during a time course assay of 7 days of infection. Cells were membrane stained
with anti-HSA antibody for detection of HIV-1 infection. Percentage of infected cells was analysed by flow cytometry. Values correspond to mean 6
SEM (n=2).
doi:10.1371/journal.pone.0009276.g003
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CA antigen in supernatant were
also determined to assess viral production in one cycle of infection
(Figure 5, white bars). Our data showed that shRNAs with an
effect on HIV-1 transcription were associated with a significant
decrease in the p24
CA levels. Taken together, our results strongly
suggest that the decrease in viral production in this context is a
direct consequence of reduced LTR-driven expression when
PRKD1, MAP3K2, MAPK9, RAD23B, EZH2, PPFIA2,
PPFIBP1 and WT1 are knockdown. Furthermore, for PTPN9,
CIB2 and SGK shRNAs, neither b-Galactosidase nor p24
CA levels
were affected by shRNA expression, suggesting that these proteins
do not play an important role in transcription of HIV-1.
Discussion
Current anti-HIV therapies targeting viral proteins have
significant constraints. One strategy to overcome current limita-
tions is to target cellular proteins that are less variable than viral
proteins. Kinases and phosphatases are key drug targets and
subject of intense scrutiny due to their wide role in cell signalling
and other biochemical activities. Hence, the aim of this study was
to identify cellular proteins, in particular kinases and phosphatases
that would be essential for HIV-1 replication but innocuous for the
cell. Consequently, these proteins can potentially be used as
antiviral targets. For this purpose, we explored a shRNA library
enriched for all human kinases and phosphatases and performed
an iterative shRNA screen in Jurkat T-cells. Previous studies have
performed RNAi screens at a genome-wide-scale to identify
possible host factors that could assist HIV-1 infection [7–10].
These genetic screens were all performed with the same goal but
the resultant proteins did not overlap in great extent. These results
can be justified by the different approaches chosen in each study.
In the first three studies using siRNA libraries [7–9], where the
knockdown is transient, different host cell lines were used, different
timings of siRNA treatment were employed, and different readout
experiments were performed. In addition, in all studies different
criteria were chosen for the bottlenecks after the primary screen
which could have accentuated the differences in the final results
[19]. The more recent screen [10] used a different approach that is
closest to the study described in this manuscript. The work of
Kuan-Teh Jeang and co-workers performed a more extensive
knockdown screen with a genome-wide shRNA library in Jurkat
T-cell line. This last work seems to be most advantageous
compared to previous studies [20]. Despite the differences, all
screens applied a broad approach with an extensive RNAi library
that covers all human genes.
Our work focused on a more restricted strategy using a smaller
library, enriched against kinases and phosphatases instead of a
generalized genome-wide library. With this strategy not only we
ensured that this druggable class of proteins was the major focus of
the screening but also we bias it representation in the final results
diminishing the probability of off-target proteins. Like Yeung et al.
we decided to perform a screen with a shRNA library to
constitutively knockdown the target genes and used Jurkat cells
Figure 4. Knockdown of host-proteins do not affect integration but affect an early step in HIV-1 replication. Jurkat shRNA clones were
transduced with EGFP-expressing lentiviral particles (FugW-EGFP) pseudptyped with VSV-G and HIV-1 gp120. After 48 h, EGFP expression was
measured by flow cytometry. Values are relative to the percentage of shSCRAM EGFP positive cell and represent mean 6 SEM (n=3). Black bars
indicate values for shRNA clones transduced with a VSV-G-lentivirus and white bars indicate values to shRNA clones transduced with a GP120-
lentivirus.
doi:10.1371/journal.pone.0009276.g004
Figure 5. HIV-1 LTR-driven transcription is affected by host-proteins. Transient assays were performed in HeLa-P4 cells co-transfected with
pHIV-1NL4-3 and the different shRNA plasmids. After 48 h, cells were harvested and LTR transcription was measured by quantification of the b-
Galactosidase activity in cell lysates. Cell supernatant was also collected to measure viral production by p24
CA ELISA. Black bars indicate values for
measurements of b-Galactosidase activity in cell lysates and white bars indicate values for measurements of p24
CA in the supernatant. Values are
relative to the control shSCRAM and represent mean 6 SEM (n=3).
doi:10.1371/journal.pone.0009276.g005
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between our study and Yeung et al. reside on the use of a restricted
shRNA library and a different screen platform. We selected HIV-1
resistant cells with a reduction in viral expression (reduced
expression of HSA at cell surface) instead of cell survival after
HIV-1 infection. With this strategy we assure that HIV-1 resistant
Jurkat cells express shRNA that knockdown cellular proteins
directly contributing to productive HIV-1 replication. Instead,
selection by cell survival can recover shRNA that may interfere
with apoptosis, or other mechanisms that promote cell viability.
These differences are expected to complement and improve the
goal of discovering novel knockdown targets for HIV-1 that can be
used as antiviral targets.
With this work we identified 14 different proteins that strongly
assist HIV-1 replication. The assessment of critical steps in HIV-1
life cycle allowed us to conclude that none of these proteins seem
to a have a relevant role in HIV-1 proviral integration. Instead, all
proteins seem to play an important role before viral integration in
an early step of HIV-1, entry and/or uncoating. Moreover, our
results demonstrate that PRKD1, MAP3K2, MAPK9, RAD23B,
EZH2, PPFIA2, PPFIBP1, WT1 and STK24 have an effect on
HIV-1 LTR transcription. On contrary, PTPN9, CIB2 and SGK
do not show an important outcome on this viral replication step.
Therefore, we can infer that PRKD1, MAP3K2, MAPK9,
RAD23B, EZH2, PPFIA2, PPFIBP1, WT1 and STK24 may be
important for HIV-1 entry (or uncoating) and transcription.
Conversely, PTPN9, CIB2 and SGK are only involved in entry/
uncoating. This double functionality could be the result of
multifunctional protein acting on different replication steps of
HIV-1 replication or instead, can be an indirect effect of these
proteins on the HIV-1 LTR promoter and other cellular
promoters leading to the inhibition of additional proteins involved
HIV-1 entry.
None of the 14 proteins identified in this study have been
previously reported as directly involved in HIV-1 replication.
Although several kinases and phosphatases have been described to
contribute to productive HIV-1 replication, [21–23], we have not
selected them in this screening. Moreover, even when we
introduced a bias for selecting kinases and phosphatases, only
57% of resulting proteins belong to this class, when initially 68%
were present in the library. This might have occurred due to cell
cytotoxicity during the period of more than two months in culture
when these proteins were knocked down by shRNA. The relative
weak viability of this knockdown cells could have been
outcompeted by other shRNA clones against proteins which
function was less cytotoxic for the cell. This explanation is
particularly important for kinases and phosphatases since these
classes of proteins are crucial in processes of cell death and
survival. Therefore, interfering with HIV-1 replication by
knockdown kinases/phosphatases function can have deleterious
effects on cell viability particularly when important kinases are
targeted.
Nevertheless, when we overlap our screen with the previous
studies [7–10], we observed that two proteins were already present
in early screens. PTPN9 was identified by Konig et al. [8] and
CIB2 was reported by Zhou et al. [9]. Although, when these
authors used more restricted conditions in subsequent screens,
these proteins were not identified. The different selection strategies
used between these studies and ours can justify this incongruity.
Moreover, when we searched our proteins in the NIAID HIV
Protein Interaction Database [24] two other important proteins
emerge from our results, MAPK9 and PRKD1. In addition, a
recent meta-analysis study where several reports of cellular
proteins essential for HIV-1 replication and protein databases
were intersected, identifies CIB2 as a potential druggable protein
important for viral replication [25]. Importantly, in a core analysis
to our set of genes aiming to evaluate their biochemical
relationships and possible function in the cell, we observed that
the canonical pathways more represented in our screen (Figure
S2B and Table S4) are also clearly represented in the previous
studies [7–10], indicating a possible overlap of signal pathways
instead of a direct overlap of genes.
Even though our shRNA screen in Jurkat cells has not selected
highly-known HIV-1 helper-factors, the links described above
validate the strategy presented in this study as efficient to identify
important helper factors that assist HIV-1 replication. As
mentioned above, the 14 proteins we have identified have not
yet been described as directly involved in HIV-1 replication.
Nevertheless, the putative involvement of these proteins into
different cellular pathways could lead to a better knowledge of
their function during HIV-1 life cycle (Table S3). For example,
EZH2 was described to interact with EED, a member of the PcG
family, at the EED–EZH2 complex in mammals [26]. In turn,
EED was described to interact with HIV-1 matrix, integrase and
Nef [27–29]. Until this date the EED role in HIV-1 life cycle is not
well understood. Data suggests that EED could be involved in
cellular function(s) necessary in early steps of HIV-1 life cycle [28]
or that EED may function as a negative regulator of HIV-1
assembly and release [30]. Our results seem to indicate that EZH2
acts as a positive factor in HIV-1 entry. Another cellular protein
demonstrated to be important for HIV-1 is NDR1. A previous
work showed that NDR1 and NDR2 are incorporated into HIV-1
virions and the viral protease cleaves these proteins altering its
enzymatic activity in order to favour HIV-1 replication [31]. In
addition, NDR1 phosphorylation leads to activation of STK24
[32]. Therefore, it is conceivable that STK24 could also be
incorporated in HIV-1 and could have an important role in HIV-1
replication. SGK is transcriptionally activated by the Glucocor-
ticoid receptor (GR) [33], which has been demonstrated to interact
with HIV viral protein VPR within a complex integrating VIP-1.
A study suggested that the interaction VPR-GR could induce
apoptosis since NF-kB inhibition by VPR seemed to be GR-
dependent [34]. In addition, a recent work has also demonstrated
that VPR-GR interactions increases LTR-mediated transactiva-
tion, most likely prior to the presence of Tat [35]. The GR
recruitment by VPR into the nucleus could activate SGK that
would induce LTR-driven expression. This hypothesis correlates
with our results where SGK acts a positive factor for HIV-LTR
transcription.
Furthermore, a report using chemical inhibitors indicated that
ERK pathway via PRKD1 was dramatically activated by Tat in
monocytes [36]. Moreover, PRKD1 together with PI3K has a role
in presenting the catalytically active form of CDK9 to the HIV-1
promoter. It was also demonstrated that LTR-activation by
PRKD1 is Tat-independent [37], corroborating with our findings.
RAD23B is homologous to RAD23A (HHR23A) and both are
described to have the same function in Nucleotide Excision Repair
(NER) pathway [38]. RAD23A is important for HIV-1 replication,
it interacts physically with VPR, which seems to be critical for cell
cycle arrest [39,40]. Hence, RAD23B could be as important to
HIV-1 as RAD23A or have a different function in HIV-1 entry
and/or HIV-1 transcription as our results indicate.
Finally, the human leukocyte elastase (HLE), also known as
ELA2, has been shown to interact with HIV-1 glycoprotein gp41.
HLE is proposed to be a rate-limiting receptor for viral entry
potentially by a mechanism involving the phenomenon of receptor
co-patching [41]. The structural similarities between ELA1 and
ELA2 could lead to the hypothesis that ELA1 could have similar
New HIV-1 Host-Factors
PLoS ONE | www.plosone.org 9 February 2010 | Volume 5 | Issue 2 | e9276function to ELA2. Indeed, our results identify ELA1 as important
for HIV-1.
Regarding MAP3K2 and MAPK9, although they were not
shown to be directly involved in HIV-1 replication, many reports
have described MAPK pathway to be important for HIV-1
replication in several cell types [42–47].
Our study brings new perspectives for HIV-1-host interplay.
The exact mechanism and pathway(s) where these proteins are
involved is a continuous open question. The indication of possible
network(s) (Figure S1) between genes and the putative overlap in
some signal pathways, will lead us to future work in the cross-talk
between HIV-1 replication and cell signalling. Specifically, and
now that a picture is emerging from these studies, more work with
primary cells should be implemented to better understand the
importance of these genes in primary T-lymphocytes.
In summary, the results presented in this report bring new
insights for the complex interplay between HIV-1 and its cellular
host leading to a novel perspective for the multifunctional role of
the cellular proteins in HIV-1 replication. The identification of
new kinases and phosphatases essential for viral replication
emphasizes the cell signalling complexity and instigates for further
studies involving cellular pathways and HIV-1 replication.
Moreover, we show the feasibility to identify host factors that
are both essential to the virus and non-essential to the cell.
Importantly, these HIV-1 helper-factors being druggable can have
a significant impact for new antiviral approaches when traditional
strategies fail.
Supporting Information
Supporting Information S1 Material and Methods
Found at: doi:10.1371/journal.pone.0009276.s001 (0.03 MB
DOC)
Figure S1 Biochemical relationships between identified proteins.
Core analysis was performed with Ingenuity Pathway Analyses
(IPA) software (Ingenuity Systems, Inc., CA, USA) to analyse
putative relationships between all genes identified in our shRNA
screen. The analysis includes only molecules and/or relationships
from human specie. Direct (continuous lines) and indirect (dashed
lines) relationships are taken into account. Core analysis identified
two hypothetical networks between all genes. A. Associated
Function Network 1 corresponding to Amino Acid Metabolism,
Post-Translational Modification, and Small Molecule Biochemis-
try: includes ELA1 (CELA1), MAP3K2, MAPK9, PRKD1,
PTPN9, PTPRE, RAD23B, SGK1, STK24 and WT1. B.
Associated Function Network 2 corresponding to Cell Cycle, Cell
Signaling, Cellular Growth and Proliferation and includes CIB2,
EZH2, PPFIA2 and PPFIBP1.
Found at: doi:10.1371/journal.pone.0009276.s002 (0.67 MB TIF)
Figure S2 Biofunctional analysis of identified genes. A. Molec-
ular and cellular functions of identified genes. Bars indicate de
representativeness of genes described in this study. B. Represen-
tation of the different canonical pathways wherein the identified
genes are present. Bars indicate representativeness in the canonical
pathways of genes described in this study. Line represents ratio
values between the genes present in each pathway and its
representativeness in all canonical pathways. In both analyses
threshold value is 0.05. Fisher’s Exact Test-P value was performed
with IPA software.
Found at: doi:10.1371/journal.pone.0009276.s003 (1.79 MB TIF)
Figure S3 Resistance of the different shRNA clones to HIV-1
replication. To evaluate the effect of the different shRNAs to HIV-
1 replication, shRNA clones were infected with HIV-1NL4-3 and
after 7 days of infection viral replication was measured by p24CA
ELISA. A. Evaluation of PTPN9 shRNA clones resistance to HIV-
1 replication. shRNA clones PTPN9-B and PTPN9-C were
selected to perform the subsequent studies and from than on
designated as PTPN9-1 and PTPN9-2, respectively. B. Evaluation
of PRKD1 shRNA clones resistance to HIV-1 replication. shRNA
clones PRKD1-C and PRKD1-E were selected to perform the
subsequent studies and from than on designated as PRKD1-1 and
PRKD1-2, respectively. C. Evaluation of MAP3K2 shRNA clones
resistance to HIV-1 replication. shRNA clones MAP3K2-A and
MAP3K2-D were selected to perform the subsequent studies and
from than on designated as MAP3K2-1 and MAP3K2-2,
respectively. D. Evaluation of MAPK9 shRNA clones resistance
to HIV-1 replication. shRNA clones MAPK9-A and MAPK9-D
were selected to perform the subsequent studies and from than on
designated as MAPK9-1 and MAPK9-2, respectively. E. Evalu-
ation of ELA1 shRNA clones resistance to HIV-1 replication.
shRNA clones ELA1-A and ELA-D were selected to perform the
subsequent studies and from than on designated as ELA1-1 and
ELA1-2, respectively. F. Evaluation of RAD23B shRNA clones
resistance to HIV-1 replication. shRNA clones RAD23B-C and
RAD23B-D were selected to perform the subsequent studies and
from than on designated as RAD23B-1 and RAD23B-2,
respectively. G. Evaluation of CIB2 shRNA clones resistance to
HIV-1 replication. shRNA clones CIB2-A and CIB2-B were
selected to perform the subsequent studies and from than on
designated as CIB2-1 and CIB2-2, respectively. H. Evaluation of
EZH2 shRNA clones resistance to HIV-1 replication. shRNA
clones EZH2-A and EZH2-C were selected to perform the
subsequent studies and from than on designated as EZH2-1 and
EZH2-2, respectively. I. Evaluation of PPFIA2 shRNA clones
resistance to HIV-1 replication. shRNA clones PPFIA2-A and
PPFIA2-C were selected to perform the subsequent studies and
from than on designated as PPFIA2-1 and PPFIA2-2, respectively.
J. Evaluation of PPFIBP1 shRNA clones resistance to HIV-1
replication. shRNA clones PPFIBP1-C and PPFIBP1-E were
selected to perform the subsequently studies and from than on
designated as PPFIBP1-1 and PPFIBP1-2, respectively. K.
Evaluation of WT1 shRNA clones resistance to HIV-1 replication.
shRNA clones WT1-A and WT1-C were selected to perform the
subsequent studies and from than on designated as WT1-1 and
WT1-2 respectively. L. Evaluation of STK24 shRNA clones
resistance to HIV-1 replication. shRNA clones STK24-A and
STK24-C were selected to perform the subsequent studies and
from than on designated as STK24-1 and STK24-2, respectively.
M. Evaluation of SGK shRNA clones resistance to HIV-1
replication. shRNA clones SGK-C and SGK-D were selected to
perform the subsequent studies and from than on designated as
SGK-1 and SGK-2 respectively. All values are relative to infected
Jurkat cells and represent mean 6 SEM (n$3).
Found at: doi:10.1371/journal.pone.0009276.s004 (6.82 MB TIF)
Figure S4 mRNA knockdown in individual clones stably
expressing shRNA. After recloning shRNA in Jurkat cells, mRNA
was extracted from the different shRNA clones and cDNA was
purified for posterior quantification by real-time PCR. All graphs
represent the two more efficient shRNAs for each gene and
mRNA levels are relative to Jurkat cells Values represent mean 6
SEM. A. Reduction of mRNA levels in PTPN9 shRNA clones
(n=2). B. Reduction of mRNA levels in PRKD1 shRNA clones
(n=2). und indicate that mRNA levels for these gene were
undetectable by qPCR assay. C. Reduction of mRNA levels in
MAP3K2 shRNA clones (n=2). D. Reduction of mRNA levels in
MAPK9 shRNA clones (n=3). E. Reduction of mRNA levels in
ELA1 shRNA clones (n=3). F. Reduction of mRNA levels in
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CIB2 shRNA clones (n=2). H. Reduction of mRNA levels in
EZH2 shRNA clones (n=3). I. Reduction of mRNA levels in
PPFIA2 shRNA clones (n=2). J. Reduction of mRNA levels in
PPFIBP1 shRNA clones (n=3). K. Reduction of mRNA levels in
WT1 shRNA clones (n=3). L. Reduction of mRNA levels in
STK24 shRNA clones (n=2). M. Reduction of mRNA levels in
SGK shRNA clones (n=2).
Found at: doi:10.1371/journal.pone.0009276.s005 (6.39 MB TIF)
Figure S5 Monitoring HIV-HSA infection in shRNA Jurkat
clones. HIV-1 replication kinetics in shRNA clones during 7 days
of infection. shRNA clones were infected with HIV-HSA and
p24CA expression was measured at day 2, 4 and 7. Values are
relative to control shSCRAM infected cells (&) and represent
mean 6 SEM (n=3). A. Evaluation of HIV-HSA replication in
shRNA clones for PTPN9, PRKD1, MAP3K2, MAPK9 and
ELA1. B. Evaluation of HIV-HSA replication in shRNA clones for
RAD23B, CIB2 and EZH2. C. Evaluation of HIV-HSA
replication in shRNA clones for PPFIA2, PPFIBP1, WT1,
STK24 and SGK.
Found at: doi:10.1371/journal.pone.0009276.s006 (0.81 MB TIF)
Figure S6 CD4 surface expression in Jurkat shRNA clones
during HIV-1. Jurkat shRNA clones were infected with HIV-
1NL4-3 and CD4 positive cells were measured by flow cytometry
at day 0, 2, 4 and 7. Dash lines indicate the values for shSCRAM
clone. Values represent mean 6 SEM (n=3).
Found at: doi:10.1371/journal.pone.0009276.s007 (5.87 MB TIF)
Table S1 shRNA sequences used for each gene in study. For
each gene three to five shRNA sequences were cloned in pLK01
for knockdown of gene expression.
Found at: doi:10.1371/journal.pone.0009276.s008 (0.07 MB
DOC)
Table S2 Oligonucleotide sequence for target-gene cDNA
amplification by qPCR.
Found at: doi:10.1371/journal.pone.0009276.s009 (0.04 MB
DOC)
Table S3 Genes identified in this screen important for HIV-1
replication. Gene information is described, in particular subcellu-
lar localization, molecular class and cellular function.
Found at: doi:10.1371/journal.pone.0009276.s010 (0.03 MB
PDF)
Table S4 Canonical Pathways involving identified genes.
Representation of the different canonical pathways where the
genes identified in this study can play a role. The representative-
ness of each pathway in our study population and the ratio of our
genes in the canonical pathway were calculated by IPA-Ingenuity
Systems Software.
Found at: doi:10.1371/journal.pone.0009276.s011 (0.04 MB
XLS)
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